<DOC>
	<DOCNO>NCT00125437</DOCNO>
	<brief_summary>The purpose study determine whether large dose aldosterone antagonist spironolactone combine low dose ACE inhibitor effective reverse leave ventricular remodel severe congestive heart failure patient nonischemic cardiomyopathy .</brief_summary>
	<brief_title>Larger Dose Spironolactone Treatment Patients With Nonischemic Cardiomyopathy</brief_title>
	<detailed_description>In investigator ' recent daily clinical practice , find large dose aldosterone antagonist spironolactone combine low dose ACE inhibitor high tolerable dose beta blocker could reverse leave ventricular remodel effectively small dose spironolactone . The ventricular remodeling could get back normal , especially patient none-ischaemic cardiomyopathy . The investigator hypothesize long term use large dose aldosterone antagonist spironolactone could reverse leave ventricular remodel stimulate new myocyte formation . Thus , design study verify efficacy safety reverse leave ventricular remodel severe congestive heart failure patient nonischemic cardiomyopathy . To avoid hyperkalemia , investigator routinely use large dos diuretic combination lower dose ACE inhibitor offset potassium-sparing effect spironolactone follow patient closely .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>New York Heart Association ( NYHA ) Functional class Ⅲ Ⅳ Left Ventricular Ejection Fraction ( LVEF ) &lt; 35 % Nonischemic cardiomyopathy Preserved renal function : Cr ≤2.5 mg/dL male ; Cr ≤2.0mg/dL females Hyperkalemia ( ≥5.0 mEg/L ) Left ventricular systolic dysfunction pericardial disease , congenital heart disease , pulmonary heart disease , heart valvular disease , acute coronary syndrome short life expectancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>aldosterone antagonist</keyword>
	<keyword>spironolactone</keyword>
	<keyword>leave ventricular remodeling</keyword>
</DOC>